News und Analysen

It's been a tough stretch for pharmaceutical giant Pfizer (NYSE: PFE). The company enjoyed a vaccine windfall during the COVID-19 pandemic, but revenue and profits cratered as the pandemic eased and

The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck's (NYSE: MRK) roughly 4% yield is highly attractive. And LTC Properties' (NYSE:

If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge

After being a laggard to start the year, Advanced Micro Devices (NASDAQ: AMD) has rallied strongly during the summer. However, its shares took a dip following the announcement of its second-quarter

Priorities change as you enter new seasons of life. That's especially true for your retirement years. And the changing priorities can include what you want from your investments. Income usually

Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for

Parks! America (OTC:PRKA), an operator of three regional safari parks in Georgia, Missouri, and Texas, reported earnings for its fiscal third quarter on August 8, 2025, with income before income

Valuations have been a concern for many investors across the board, but as investors, we should constantly be putting in the work so that we are prepared for when opportunities persist.

In today's

Advanced Micro Devices (NASDAQ: AMD) reported quarterly financial results that disappointed stock market investors.

*Stock prices used were the afternoon prices of Aug. 4, 2025. The video was

In this video, I will go over Advanced Micro Devices' (NASDAQ: AMD) earnings report and explain what the market missed and why I remain extremely bullish. Watch the short video to learn more

UnitedHealth (NYSE: UNH) stock is trading near its 52-week low.

*Stock prices used were the afternoon prices of Aug. 4, 2025. The video was published on Aug. 6, 2025.

Continue reading

Source Fool.c

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the special offer link below.

Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the

MicroVision (NASDAQ:MVIS), a company specializing in lidar (light detection and ranging) sensor hardware and integrated perception software for automotive, industrial, and defense markets, reported

Coherus Oncology (NASDAQ:CHRS), a biotechnology company focused on developing and commercializing innovative immuno-oncology therapies, reported earnings for Q2 2025 on August 7, 2025. The results

CytomX Therapeutics (NASDAQ:CTMX), a biotechnology company focused on developing targeted oncology therapies, reported its second quarter 2025 results on August 7, 2025. In the period, the most

Natera (NASDAQ:NTRA), a leader in genetic testing across oncology, women's health, and organ health, reported its earnings for Q2 2025 on August 7, 2025. The most significant news was a 32.2%

Organogenesis (NASDAQ:ORGO), a regenerative medicine company specializing in advanced wound care and surgical and sports medicine products, reported Q2 2025 results on August 7, 2025. The standout

Trupanion (NASDAQ:TRUP), a provider of pet health insurance, reported results for the second quarter of fiscal 2025 on August 7, 2025. The company surprised analysts with diluted earnings per share

Dynavax Technologies (NASDAQ:DVAX), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on

Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025

scPharmaceuticals (NASDAQ:SCPH), a commercial-stage pharmaceutical company focused on subcutaneous drug delivery for heart failure and chronic kidney disease patients, delivered its second quarter